Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-16
1996-08-06
Rollins, John W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 78, 424450, 536 21, 536 51, 530300, 530331, 530329, A01N 3718, A01N 5726
Patent
active
055433910
ABSTRACT:
This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the targeted drug is only released in cells infected with a particular microorganism. Alternative embodiments of such specific drug delivery compositions also contain polar lipid carrier molecules effective in achieving intracellular organelle targeting in infected phagocytic mammalian cells. Particular embodiments of such conjugates comprise antimicrobial drugs covalently linked both to a microparticle via an organic linker molecule and to a polar lipid compound, to facilitate targeting of such drugs to particular subcellular organelles within the cell. Also provided are porous microparticles impregnated with antimicrobial drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Methods of inhibiting, attenuating, arresting, combatting and overcoming microbial infection of phagocytic mammalian cells in vivo and in vitro are also provided.
REFERENCES:
patent: 4780455 (1988-10-01), Liberman et al.
patent: 4793986 (1988-12-01), Serino et al.
patent: 4847240 (1989-07-01), Ryser et al.
patent: 5053394 (1991-10-01), Ellestad et al.
patent: 5258453 (1993-11-01), Kopecek et al.
Baer, 1955, Can. J. Biochem. Phys. 34: 288.
Smith and Khorana, 1958, J. Amer. Chem. Soc. 80: 1141.
Remy et al., 1962, J. Org. Chem. 27: 2491-2500.
Mukhergee & Heidelberger, 1962, Cancer Res. 22: 815-22.
Jones and Hirsch, 1972, "The Interaction between Toxoplasma gondii and Mammalian Cells," J. Exp. Med. 136: 1173-1194.
Mauel et al., 1973, "Quantitative Release of Live Microorganisms from Infected Macrophages by Sodium Dodecyl Sulfate," Nature New Biol. 244: 93-94.
Kishimoto, 1975, Chem. Phys. Lipids 15: 33-36.
Matsuura et al., 1976, J. Chem. Soc. Chem. Comm. xx: 451-459.
Nogueira and Cohn, 1976, "Trypanosoma cruzi: Mechanisms of Entry and Intracellular Fate in Mammalian Cells," J. Exp. Med. 143: 1402-1420.
Halstead et al., 1977, "Dengue Viruses and Mononuclear Phagocytes: I. Infection Enhancement by Non-Neutralizing Antibody," J. Exp. Med. 146: 201-217.
Wyrick and Brownridge, 1978, "Growth of Chlamydia psittaci in Macrophages," Infect. Immunol. 19: 1054-1060.
Chang, 1979, "Leishmania donovani: Promastigote-Macrophage Surface Interactions in Vitro," Exp. Parisitol. 48: 175-189.
Verbloom et al., 1981, Synthesis 1032: 807-809.
Shen et al., 1981, "Cis-Aconityl Spacer between Daunomycin and Macromolecular Carriers: A Model of pH Sensitive Linkage Releasing Drug from a Lysomotropic Conjugate," Biochem. Biophys. Res. Commun. 102: 1048-1052.
Trouet et al., 1982, "A covalent linkage between daunorubicin and proteins that is stable in serum and reversable by lysosomal hydrolases, as required for a lysomotropic drug-carrier conjugate: In vitro and in vivo studies," Proc. Natl. Acad. Sci. USA 79: 626-629.
Rahman et al., 1982, Life Sci. 31: 2061-71.
Illum et al., 1982, "Blood clearance and organ deposition of intravenously administered colloidal particles: the effects of particle size, nature and shape," Int. J. Pharm. 12: 135-146.
Horwitz, 1983, "The Legionnaires' Disease Bacterium (Legionella pneumophila) Inhibits Phagosome-Lysosome Fusion in Human Monocytes," J. Exp. Med. 158: 2108-2126.
Shanley and Pesanti, 1983, "Murine Peritoneal Macrophages Support Murine Cytomegalovirus Replication," Infect. Immunol. 41: 1352-1359.
Horwitz and Maxfield, 1984, "Legionella pneumophila Inhibits Acidification of its Phagosome in Human Monocytes," J. Cell Biol. 99: 1936-1943.
Brewster et al., 1985, "Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified .beta.-Cyclodextrins," J. Pharm. Sci. 77: 981-985).
Gendelman et al., 1985, "Slow, persistent replication of lentiviruses: Role of tissue macrophages and macrophage precursors in bone marrow," Proc. Natl. Acad. Sci. USA 82: 7086-7090.
Salord et al., 1986, Biochim. Biophys. Acta 886: 64-75.
Saffran et al., 1986, "A New Approach to the Oral Administration of Insulin and Other Peptide Drugs," Science 233: 1081-1084.
Koenig et al., 1986, "Detection of AIDS Virus in Macrophages in Brain Tissue from AIDS Patients with Encephalopathy," Science 233: 1089-1093.
Murray et al., 1987, "Experimental Visceral Leishmaniasis: Production of Interleukin 2 and Interferon .gamma., Tissue Immune Reaction, and Response to Treatment with Interleukin 2 and Interferon .gamma.," J. Immunol. 138: 2290-2296.
Zasloff, 1987, "Magainins, a class of antimicrobial peptides from Xenopus skin: Isolation, characterization of two active forms, and partial cDNA sequence of a precursor," Proc. Natl. Acad. Sci. USA 84: 5449-5453.
Payne et al, 1987, "Phagocytosis of Legionella pneumophila is Mediated by Human Monocyte Complement Receptors," J. Exp. Med. 166: 1377-1389.
Hunter et al., 1988, "Vesicular Systems (Niosomes and Liposomes) for Delivery of Sodium Stibogluconate in Experimental Murine Visceral Leishmaniasis," J. Pharm. Phamacol. 40: 161-165.
Baroni et al., 1988, "Expression of HIV in Lymph Node Cells of LAS Patients: Immunohistology, In Situ Hybridization, and Identification of Target Cells," Am. J. Pathol. 133: 498-506.
Lee et al., 1989, "Antibacterial peptides from pig intestines: Isolation of a mammalian cecropin," Proc. Natl. Acad. Sci. USA 86: 9159-9162,
Bowman et al., 1990, "Cell-free immunity in Cecropia: A model system for antibacterial proteins," Eur. J. Biochem. 201: 23-31.
Schmitt et al., 1990, "Multiplication of Human Immunodeficiency Virus in Primary Cultures of Human Kupffer Cells--Possible Role of Liver Macrophage Infection in the Physiopathology of AIDS," Res. Virol. 141: 143-152.
King et al., 1990, "In Vivo Selection of Lymphocyte-Tropic and Macrophage-Tropic Variants of Lymphocytic Choriomeningitis Virus during Persistent Infection," J. Virol. 64: 5611-5616.
Clarke et al., 1990, "Detection of HIV-1 in human lung macrophages using the polymerase chain reaction," AIDS 4: 1133-1136.
Schlessinger and Horowitz, 1990, "Phagocytosis of Leprosy Bacilli is Mediated by Complement Receptors CR1 and CR3 on Human Monocytes and Complement Component C3 in Serum," J. Clin. Invest. 85: 1304-1314.
Cordier et al., 1990, "In vivo Activation of Alveolar Macrophages in Ovine Lentivirus Infection," Clin. Immunol. Immunopathol. 55: 355-367.
Panuska et al., 1990, "Productive Infection of Isolated Human Alveolar Macrophages by Respiratory Syncytial Virus," J. Clin. Invest. 86: 113-119.
Buchmeier and Heffron, 1990, "Induction of Salmonella Stress Proteins upon Infection of Macrophages," Science 248: 730-732.
Mauel, 1990, "Macrophage-Parasite Interactions in Leishmania Infections," J. Leukocyte Biol. 47: 187-193.
Lehrer et al., 1991, "Defensins: Endogenous Antibiotic Peptides of Animal Cells," Cell 64: 229-230.
Bromberg et al., 1991, "Detection of Borditella pertussis Associated with the Alveolar Macrophages of Children with Human Immunodeficiency Virus Infection," Infect. Immun. 59: 4715-4719.
Frehel et al., 1991, "Intramacrophage Growth of Mycobacterium avium during Infection of Mice," Infect. Immun. 59: 2
Gallicchio Vincent S.
Meredith Michael J.
Stowell Michael H. B.
Yatvin Milton B.
Rollins John W.
State of Oregon Acting by and Through the Oregon State Board of
LandOfFree
Covalent microparticle-drug conjugates for biological targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Covalent microparticle-drug conjugates for biological targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalent microparticle-drug conjugates for biological targeting will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2191164